Antogin ER (Extended Release)
Tablet (Extended Release)
Renata LimitedGeneric:
RanolazineWeight:
500 mgbest Price:
? 16.00Generic
Ranolazine
Indications
Ranolazine is indicated for the treatment of chronic angina. Ranolazine may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. It has been shown to decrease angina episodes in patients with coronary artery disease on maximal doses of amlodipine. Because Ranolazine prolongs the QT interval, it should be reserved for patients who have not achieved an adequate response with other antianginal drugs.The effect on angina rate or exercise tolerance appeared to be smaller in women than men.
Contraindications
Cardiac Disorders: bradycardia, palpitations Ear and Labyrinth Disorders: tinnitus, vertigo Gastrointestinal Disorders: abdominal pain, dry mouth, vomiting General Disorders and Administrative Site Adverse Events: peripheral edema Respiratory, Thoracic, and Mediastinal Disorders: dyspnea Vascular Disorders: hypotension, orthostatic hypotension
Side Effects
Pregnancy Category C. There are no adequate studies assessing the effect of ranolazine on the developing fetus. There are no adequate well-controlled studies in pregnant women. Ranolazine should be used during pregnancy only when the potential benefit to the patient justifies the potential risk to the fetus.lt is not known whether ranolazine is excreted in human milk. Because of the potentiality for serious adverse reactions from ranolazine in nursing infants, a decision should be made whether to discontinue nursing or to discontinue Ranolazine, taking into account the importance of the drug to the mother.
Pregnancy And Lactation
Ranolazine blocks QTc and prolongs the QTc interval in a dose-related manner. Clinical experience in an acute coronary syndrome population did not show an increased risk of proarrhythmia or sudden death. Co-administration of ranolazine with digoxin increases the plasma concentrations of digoxin by approximately 1.5-fold and the dose of digoxin may have to be reduced accordingly. The dose of other P-gp substrates may have to be reduced as well when ranolazine Is co-admlnistered. Caution should be exercised when co-adminlstering ranolazine with P-gp inhibitors such as ritonavir or cydosporine.
Therapeutic
Pediatric use: Safety and effectiveness in pediatric patients have not been established. Renal Impairment: Mild to moderate (CrCl 30-80 mL/min): Dose titration needed Severe (CrCl <30 mL/min): Contraindicated Hepatic Impairment: Mild: Dose titration needed Moderate to severe: Contraindicated
Storage Conditions
Symptoms: Dizziness, nausea, vomiting, diplopia, lethargy, syncope, severe tremor, incoordination, dysplasia, hallucination. Management: Symptomatic and supportive treatment.
Over The Counter Products
